Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma
| Autor: | Xuyuan Li, Hong-biao Wang, Wen Lin, Ying-cheng Lin, Wen-zhao Lin, Sui-ling Lin |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Esophageal Neoplasms Anemia medicine.medical_treatment Docetaxel Neutropenia Deoxycytidine Capecitabine Internal medicine Antineoplastic Combined Chemotherapy Protocols Carcinoma medicine Humans Adverse effect Aged Chemotherapy business.industry Hematology General Medicine Middle Aged medicine.disease Carcinoma Squamous Cell Female Taxoids Esophageal Squamous Cell Carcinoma Fluorouracil Cisplatin business Febrile neutropenia medicine.drug |
| Zdroj: | Medical oncology (Northwood, London, England). 30(4) |
| ISSN: | 1559-131X |
| Popis: | We performed a phase II trial of docetaxel in combination with capecitabine to evaluate the antitumor response, toxicity, and survival in pre-treated patients with advanced esophageal squamous cell carcinoma. Patients with advanced esophageal squamous cell carcinoma who had failed first-line chemotherapy with cisplatin and 5-fluorouracil were enrolled in this study. Treatment consisted of oral capecitabine (825 mg/m2 twice daily on days 1–14) plus 1-h intravenous docetaxel (60 mg/m2 on day 1) every 3 weeks for up to 6 cycles. Between June 2008 and August 2011, thirty eligible patients with a median age of 58 years (range 38–68 years) were enrolled. Patients received a median of three cycles of treatment (range 1–6). The median follow-up was 15.4 months (range 1.0–31.5 months). Intent-to-treat efficacy analysis demonstrated an overall response rate of 23.3 % (0 complete response and 7 partial response) and stable disease of 43.4 % (n = 13). The median time to progression was 3.0 months (95 % CI 1.9–4.1 months). The median survival was 8.3 months (95 % CI 6.8–9.8 months). Severe adverse events (grade 3/4) reported were as follows: neutropenia (33.3 %, n = 10, including febrile neutropenia 6.7 %, n = 2), anemia (16.7 %, n = 5), thrombocytopenia (10 %, n = 3), hand–foot syndrome (13.3 %, n = 4), and fatigue (10 %, n = 3). Docetaxel plus capecitabine had a manageable adverse event profile and promising activity in advance esophageal squamous cell carcinoma as a second-line treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink